Comparative Pharmacology
Head-to-head clinical analysis: MEFOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MEFOXIN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEFOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MEFOXIN IN PLASTIC CONTAINER.
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs MEFOXIN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is active against a broad spectrum of gram-positive and gram-negative aerobic and anaerobic bacteria.
Cefoxitin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It is resistant to beta-lactamases produced by Gram-negative and Gram-positive bacteria.
1-2 g IV every 6-8 hours (Cefoxitin).
1-2 g IV every 6-8 hours (adults).
None Documented
None Documented
Terminal elimination half-life: 0.7-1.1 hours (normal renal function). In anuria: 13-23 hours. Clinical context: Dosing interval adjustment required for CrCl <50 mL/min.
0.7–1.2 hours in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Renal: 85% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: <1%.
Primarily renal; 85% of a dose excreted unchanged in urine within 6 hours via glomerular filtration and tubular secretion. Biliary excretion accounts for <2%; fecal elimination minimal.
Category C
Category C
Cephamycin Antibiotic
Cephamycin Antibiotic